PSTV Gains FDA Orphan Status for Malignant Glioma Treatment (Gurufocus) - Apr 7, 2026 - "The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC)."
Orphan drug • Glioblastoma
|